ATE532527T1 - Simmondsin zur verwendung als hemmstoff der angiogenese - Google Patents

Simmondsin zur verwendung als hemmstoff der angiogenese

Info

Publication number
ATE532527T1
ATE532527T1 AT03762641T AT03762641T ATE532527T1 AT E532527 T1 ATE532527 T1 AT E532527T1 AT 03762641 T AT03762641 T AT 03762641T AT 03762641 T AT03762641 T AT 03762641T AT E532527 T1 ATE532527 T1 AT E532527T1
Authority
AT
Austria
Prior art keywords
desmethylsimmondsin
ferulate
dimethylsimmondsin
didesmethylsimmondsin
humans
Prior art date
Application number
AT03762641T
Other languages
English (en)
Inventor
Oosterlynck Andre D
Stefaan Raes
Original Assignee
Oosterlynck Andre D
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oosterlynck Andre D filed Critical Oosterlynck Andre D
Application granted granted Critical
Publication of ATE532527T1 publication Critical patent/ATE532527T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT03762641T 2002-07-08 2003-07-07 Simmondsin zur verwendung als hemmstoff der angiogenese ATE532527T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BE2002/0428A BE1015023A3 (fr) 2002-07-08 2002-07-08 L'usage de la farine raffinee et deshuilee du jojoba ou un ou plusieurs de ces composants bio-actives comme agent inhibiteur de l'angiogenese dans la lutte contre le cancer.
PCT/EP2003/007270 WO2004004746A1 (en) 2002-07-08 2003-07-07 Simmondsin for use as an angiogenesis inhibitor

Publications (1)

Publication Number Publication Date
ATE532527T1 true ATE532527T1 (de) 2011-11-15

Family

ID=30005466

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03762641T ATE532527T1 (de) 2002-07-08 2003-07-07 Simmondsin zur verwendung als hemmstoff der angiogenese

Country Status (8)

Country Link
US (1) US7387999B2 (de)
EP (1) EP1526862B1 (de)
AT (1) ATE532527T1 (de)
AU (1) AU2003246395A1 (de)
BE (1) BE1015023A3 (de)
ES (1) ES2376054T3 (de)
IL (1) IL166182A (de)
WO (1) WO2004004746A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1616874A1 (de) * 2004-07-14 2006-01-18 Universiteit Gent Mono- und bicyclische Verbindungen mit therapeutischer Aktivität und pharmazeutische Zubereitungen
US7774275B2 (en) * 2005-02-28 2010-08-10 Searete Llc Payment options for virtual credit
US8617487B2 (en) 2009-03-25 2013-12-31 Venture Lending & Leasing Vi, Inc. Saliva sample collection systems
WO2017191501A2 (en) 2016-05-04 2017-11-09 D'oosterlynck André Simmondsin formulation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE1006958A3 (nl) * 1993-04-29 1995-01-31 Ku Leuven Research & Dev Vzw Werkwijze voor het beinvloeden van de voedselopname door mensen en dieren.
BE1008895A6 (nl) * 1994-11-17 1996-08-06 Oosterlynck Andre D Methode voor het afscheiden van de toxische harsachtige fractie uit de voorbereide jojoba noot massa of uit de jojoba perskoek.
EP1616874A1 (de) * 2004-07-14 2006-01-18 Universiteit Gent Mono- und bicyclische Verbindungen mit therapeutischer Aktivität und pharmazeutische Zubereitungen

Also Published As

Publication number Publication date
IL166182A (en) 2013-08-29
AU2003246395A1 (en) 2004-01-23
WO2004004746A1 (en) 2004-01-15
US20060088613A1 (en) 2006-04-27
IL166182A0 (en) 2006-01-15
BE1015023A3 (fr) 2004-08-03
EP1526862A1 (de) 2005-05-04
EP1526862B1 (de) 2011-11-09
US7387999B2 (en) 2008-06-17
ES2376054T3 (es) 2012-03-08

Similar Documents

Publication Publication Date Title
ATE253545T1 (de) Biarylessigsäure-derivate und ihre verwendung als cox-2 inhibitoren
BRPI0515500A (pt) derivados piridazina para inibição de estearoil-coa-desaturase
EA200400807A1 (ru) Композиция для лечения нейроцереброваскулярных нарушений
ATE365742T1 (de) 4-aminothieno(2,3-d) pyrimidin -6-carbonitril- derivative zur verwendung als pde7 inhibitoren
EA200200983A1 (ru) Эмульсия, содержащая растительный экстракт, способ изготовления такой эмульсии и способ получения растительного экстракта
ATE318267T1 (de) Einige alkylendiamin-substituierte heterocyclen
MXPA05010958A (es) Derivados indazol como inhibidores jnk.
ATE517861T1 (de) Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
BRPI0510623A (pt) compostos de derivados de prolina e morfolina
DE60021873D1 (de) Zubereitung zur prophylaxe oder behandlung der demenz-erkrankung enthaltend ein hydroxyzimtsäurederivat oder einen extrakt einer pflanze der gattung angelica, der diese säure enthält.
GB0112348D0 (en) Compounds
DE60140871D1 (de) Arylmethylamin-derivate zur verwendung als inhibitoren von tryptase
EA200000358A1 (ru) Способ получения диарилпиридинов, полезных в качестве ингибиторов cox-2
Singh et al. Hepatoprotective effect of Physalis divaricata in paracetamol induced hepatotoxicity: In vitro, in silico and in vivo analysis
DE60139070D1 (de) Thienodibenzazulenverbindungen als tumornekrosefaktorhemmer
DK1809288T3 (da) Anvendelse af 1,4-bis-(3-aminoalkyl)piperazinderivater ved behandling af neurodegenerative sygdomme
ATE516027T1 (de) Orazamid orotat zur vorbeugung von leberschäden
ATE512147T1 (de) Makrozyklische aminiopyridyl-beta-sekretase- hemmer zur behandlung von morbus alzheimer
IL166182A0 (en) Simmondsin for use as an angiogenesis inhibitor
BRPI0411087A (pt) aperfeiçoamentos em ou relacionados a compostos orgánicos
NO20050270L (no) Nye forbindelser, deres anvendelse og fremstilling
ATE423102T1 (de) 4-substituirte-5-cyano-1h-pyrimidin-6-(th)iones als als gsk-3-hemmer
ES2333026T3 (es) Derivados de ciclohexil-1,4-diamina sustituidos.
RU2008137281A (ru) Профилактическое лечение и ремиссия аллергических заболеваний
ATE469882T1 (de) Neue verbindungen, die sich f r die behandlung von durch ppar vermittelten krankheiten eignen